GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has announced its strong support for the newly unveiled America First Global Health Strategy by U.S. Secretary of State Marco Rubio. The strategy emphasizes American innovation, domestic pharmaceutical manufacturing, and global partnerships to strengthen health security and safeguard U.S. national interests. GeoVax’s pipeline, including its Mpox/Smallpox vaccine (GEO-MVA), next-generation multi-antigen COVID-19 vaccine (GEO-CM04S1), and other infectious disease vaccines, directly aligns with the policy’s pillars of making America safer, stronger, and more prosperous.
Advancing pandemic preparedness is a key focus of the strategy, highlighting the urgent need for rapid outbreak detection and deployment of medical countermeasures. GeoVax is rapidly developing a continuous cell-line (AGE1) manufacturing technology to enhance scalability, speed, and resilience, addressing longstanding supply chain vulnerabilities in U.S. biodefense. Utilizing this advanced manufacturing process, GeoVax’s MVA-based platform is uniquely suited for rapid vaccine response against infectious disease threats including Mpox, smallpox, Zika, and hemorrhagic fever viruses. The company is also committed to developing regional supply capabilities to ensure timely and equitable access to vaccines worldwide. Its GEO-MVA program for Mpox and smallpox recently received favorable EMA scientific advice recommending an expedited regulatory pathway via an immuno-bridging study, potentially accelerating approval and commercialization.
Promoting American innovation abroad is another pillar of the strategy, emphasizing leveraging U.S. foreign assistance procurements to expand global access to American-made health solutions. GeoVax is positioned as a U.S.-based alternative to the existing foreign monopoly in poxvirus vaccines, supporting national security priorities while strengthening U.S. competitiveness in emerging global health markets. The strategy also calls for bilateral health agreements and integration with local health systems, and GeoVax’s multi-antigen vaccine design offers other countries efficient, cost-effective solutions that reduce dependency on fragmented programs, complementing U.S. goals of building resilient, country-led health systems.
David Dodd, Chairman & CEO of GeoVax, stated, “The America First Global Health Strategy represents a historic opportunity to align U.S. innovation with global health needs in a way that strengthens America’s leadership while protecting our citizens and economy. GeoVax is proud to be at the forefront of this vision, with vaccine and immunotherapy programs that deliver innovation, security, and scalability. Our mission is directly aligned with this strategy - to make America safer, stronger, and more prosperous while saving lives around the world.”
GeoVax’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster in patients with chronic lymphocytic leukemia, and a more robust booster among healthy patients. The company is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. For more information, visit www.geovax.com.
